

**Table S1. The clinicopathological data of the 8 patients selected for TEM assay**

Characteristics	Patient number							
	1	2	3	4	5	6	7	8
<b>Gender</b>	M	M	M	M	F	F	F	M
<b>Age(y)</b>	46	42	67	74	27	50	47	61
<b>Height (cm)</b>	168	163	165	160	153	163	168	160
<b>Weight (kg)</b>	65	54	69	60	53	60	56	55
<b>BMI</b>	23.03	20.32	25.34	23.44	22.64	22.58	19.84	21.48
<b>Tumor size(cm)</b>	4.8	5.4	8.3	4.5	3.1	5.2	4.6	7.2
<b>Tumor location</b>	L	L	UM	L	L	L	L	L
<b>Pathological type</b>	AC	AC	AC	AC	AC	AC	AC	AC
<b>Lauren classification</b>	Int	Int	Int	Int	Dif	Int	Dif	Dif
<b>Histologic grade</b>	PD	PD	MD	PD	PD	PD	MD	PD
<b>LN metastasis (NMLN / NDLN)</b>	Pre (1/23)	Pre (11/26)	Ab (0/20)	Pre (10/24)	Ab (0/32)	Pre (15/46)	Pre (12/45)	Pre (17/40)
<b>Tumor invasion</b>	AGC	AGC	AGC	AGC	AGC	AGC	AGC	AGC
<b>TNM stage</b>	IIIA	IIIC	IIB	IIIC	IIB	IIIC	IIIC	IIIC
<b>VCE</b>	Ab	Pre	Pre	Ab	Ab	Ab	Pre	Pre

Abbreviations: M, Male; F, Female; BMI, body mass index; L, Lower; UM, Up and Middle; AC, Adenocarcinoma; Int, Intestinal; Dif, Diffuse; MD, middle differentiation; PD, poor differentiation; LN metastasis, lymph node metastasis; NMLN, Number of metastatic lymph nodes; NDLN, Number of dissected lymph nodes; Pre, Presence; Ab, Absence; AGC, advantage gastric cancer; TNM stage, tumor node metastasis stage; VCE, vascular cancer embolus.